Germany's Activaero and Forest Laboratories to co-market new Colistin nebuliser for cystic fibrosis
This article was originally published in Scrip
Executive Summary
Germany's Activaero has signed an agreement with Forest Healthcare to co-market Activaero's Akita Jet inhaler with colistin for high-dose therapy of cystic fibrosis in Germany. The partners said they have been able to demonstrate the advantages of Colistin CF (the new product's trade name) over similar inhalers and plan to introduce it to centres for the treatment of cystic fibrosis.